4.11.2Segment

Animal Health Pharmaceuticals

Animal pharmaceutical companies developing and commercializing vaccines, biologics, and medications for companion and livestock animals.

4
Verticals

Overview

Animal Health Pharmaceuticals covers companies developing and commercializing vaccines, biologics, parasiticides, and medications for companion and livestock animals. It is led by global strategics — Zoetis (the leader, spun out of Pfizer), Boehringer Ingelheim, Elanco, and Merck Animal Health — across companion and production animals.

Companion-animal pharma is the growth engine, propelled by pet humanization and novel therapies (monoclonal antibodies for osteoarthritis pain like Librela/Solensia, dermatology, and parasiticides), while production-animal pharma is more mature and pressured by antibiotic-reduction trends. It is R&D-intensive, regulated, and consolidated.

Market snapshot

FragmentationConsolidatedEstimate

Within pharmaceutical manufacturing (NAICS 325412/325414); the Census Bureau does not separate animal-health pharmaceuticals, so the segment is not separately sized here.

Business model & economics

Revenue model

Vaccine, parasiticide, and therapeutic product sales

Key economics

Recurring revenue
High

recurring vaccines, parasiticides, and chronic meds

EBITDA margin
Strong

branded animal-pharma economics

Capex intensity
High

Characteristics

  • Companion-animal pharma the growth engine.
  • Novel therapies (mAbs, derm, parasiticides) drive growth.
  • Production-animal pharma mature and antibiotic-pressured.

Geographic concentration

AlabamaAlaskaArizonaFloridaGeorgiaIndianaKansasMaineMinnesotaNorth CarolinaNorth DakotaOklahomaPennsylvaniaSouth DakotaTexasWyomingConnecticutMissouriWest VirginiaIllinoisNew MexicoArkansasCaliforniaDelawareDistrict of ColumbiaHawaiiIowaKentuckyMarylandMichiganMississippiMontanaNew HampshireNew YorkOhioOregonTennesseeVirginiaWashingtonWisconsinNebraskaSouth CarolinaIdahoNevadaVermontLouisianaRhode IslandColoradoMassachusettsNew JerseyUtah

Animal-health pharmaceutical makers cluster in New Jersey and Massachusetts (human-pharma spillover), with specialized hubs in Utah and Colorado.

New JerseyMassachusettsUtahColorado

U.S. Census Bureau — 2022 Statistics of U.S. Businesses (firms by state), NAICS 325412/325414. Concentration shown by location quotient.

M&A deal context

Deal activityHigh

Who’s acquiring

  • Animal-health pharma strategics
  • Pharma & diversified acquirers
  • PE- and VC-backed innovators

What’s driving deals

  • Companion-animal novel-therapy innovation.
  • Consolidation around global strategics.
  • Acquisition of pet-pharma and biologic innovation.

Verticals in this segment

Find Animal Health Pharmaceuticals acquisition targets

Search Acquisera’s index for companies classified under Animal Health Pharmaceuticals (4.11.2) and build a targeted deal pipeline.

Search companies